Extracorporeal shockwave therapy (ESWT) has a significant positive effect to accelerate chronic wound healing. This study investigated whether the vascular endothelial growth factor (VEGF)-related pathway has involved in ESWT enhancement of diabetic wound healing. A dorsal skin defect (area, 6 × 5 cm) in a streptozotocin-induced diabetes rodent model was used. Thirty-two male Wistar rats were divided into four groups. Group I consisted of nondiabetic control; group II, diabetic control without treatment; group III, diabetic rats received ESWT; and group IV, rats received Avastin (a VEGF monoclonal antibody) on day 0 (post-wounding immediately) to day 7 and ESWT on day 3 and day 7. The wound healing was assessed clinically. The VEGF, endothelial nitric oxide synthase (eNOS), and Ki-67 were analyzed with immunohistochemical staining. The mRNA expression of mitogen-activated protein kinase-related genes was measured by real-time quantitative real-time polymerase chain reaction. The results revealed wound size was significantly reduced in the ESWT-treated rats as compared to the diabetic control (p < 0.01). The positive effect of ESWT-increasing wound healing was significantly suppressed in pretreatment of the Avastin group. Histological findings revealed significant increase in neo-vessels in the ESWT group as compared to the control. In immunohistochemical stain, significant increases in VEGF, eNOS, and Ki-67 expressions were noted in the ESWT group as compared to that in controls. However, Avastin suppressed the shockwave effect and down-regulation of VEGF, eNOS, and Ki-67 expressions in the Avastin-ESWT group as compared to that in the ESWT alone group. We found that highly mRNA expression of Kras, Raf1, Mek1, Jnkk, Jnk, and Jun at early stage in the ESWT group, as compared to the diabetic control. These evidences indicated treatment with multiple sessions of ESWT significantly enhanced diabetic wound healing associated with increased neovascularization and tissue regeneration. The bio-mechanism of ESWT-enhanced wound healing is correlated with VEGF and mitogen-activated protein kinase-mediated pathway.
Diabetes mellitus (DM) is a common disease associated with poor glucose control, and its incidence is increasing worldwide. 1 There are two main types of DM: type 1 is caused by lack of insulin secretion and type 2 diabetes is caused by decreased sensitivity of target tissues to insulin. Both of these conditions may result in a hyperglycemic state and lead to the development of various complications in different organ systems. The prevalence of diabetes is increasing rapidly worldwide, and the World Health Organization (2003) has predicted that by 2030, the number of adults with diabetes would have almost doubled worldwide, from 177 million in 2000 to 370 million. Approximately 43,000,000 patients suffer from diabetic wounds worldwide with the number expected to increase. 2 One of the most serious complications of diabetes is impaired wound healing, which leads to the development of chronic wounds in the lower extremities in 15-25% of diabetes patients. 3 Chronic wounds represent a relevant clinical and socioeconomic burden. The annual incidence of foot ulcers among people with diabetes is estimated at between 1 and 4.1%, and the annual incidence of amputation is 0.21-1.37%. 4 The amputation rate is 15-70 times higher in diabetic individuals than in the general population. 5, 6 Wound healing is a complex process, including inflammation, granulation tissue formation, angiogenesis, reepithelialization, and remodeling. Optimum chronic wound healing Wound Rep Reg (2019) 27 69-79 © 2018 by the Wound Healing Society requires a well-orchestrated integration of complex biological and molecular events for cell migration, proliferation, extracellular matrix (ECM) deposition, angiogenesis, and remodeling. 7 The process is dependent upon a series of interactions between a variety of cell types, cytokine mediators, and the ECM. 8 Wound healing processes have been reported to be regulated by a multitude of cytokines and growth factors, including epidermal growth factor, transforming growth factor-β, hepatocyte growth factor, vascular endothelial growth factor (VEGF), fibroblast growth factor, keratinocyte growth factor, interleukin family, and tumor necrosis factor-α. 9 In particular, VEGF is present at elevated levels during the first phases of wound repair, but its expression declines as the healing process is completed. 10 VEGF is considered as the key regulator of both vascular development and physiological and pathological angiogenesis during inflammation and wound healing.
11 VEGF receptor signaling could regulate cell proliferation and differentiation via activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway. 12 Bevacizumab, sold under the trade name Avastin, is a medication used to treat a number of types of cancers by slow injection into a vein. 13 Studies on effects of anti-VEGF treatment have been performed using Avastin in diabetic rat model. 14, 15 Extracorporeal shockwave therapy (ESWT) is widely accepted as a technique for treating patients with urinary stones. Recently, ESWT was applied and adapted to different clinical fields such as musculoskeletal disorders (nonunion of long bone fractures, calcifying tendonitis). 16 The cascades of biological processes elicited by ESWT are directly correlated with enhanced blood supply and tissue regeneration. Furthermore, the clinical applications of ESWT for the treatment of wounds have been described recently. 17, 18 In our previous study on a rat model, we found that ESWT enhances the survival of the ischemic flap tissue via anti-inflammatory responses and by inducing cell proliferation and neovascularization. 19 We also demonstrated that the ESWT has a significant positive effect in accelerating chronic wound healing in our clinical application. 20 Improved tissue perfusion and a significant rise of growth factors, i.e., VEGF as well as endothelial nitric oxide synthase, and proliferating cell nuclear antigen (PCNA) are supposed to explain the enhanced skin flap survival following ESWT. 21 However, the exact bio-mechanism operating during ESWT of wounds remains unclear.
In this study, we used the dorsal skin defect for evaluating wound healing in a rodent model of streptozotocin (STZ)-induced diabetes. The wound-healing process was pretreated with Avastin, a kind of VEGF inhibitor, and tested using ESWT. Here, we attempted to determine whether ESWT accelerates wound healing by increasing cell proliferation and tissue regeneration and whether it is associated with suppression of the pro-inflammatory response. This study investigated whether the bio-mechanism of ESWT-enhanced diabetic wound healing is correlated with the modulation of VEGF and MAPK-related pathway.
MATERIALS AND METHODS

General
All the animals were treated humanely according to the guidelines provided in the Guide for the Care and Use of Laboratory Animals, published by the National Institute of Health. Care and housing conditions of the animals complied with the regulations of the Institutional Animal Care and Use Committee on the protection of animals used for scientific purposes (Approval No. 2007111902) . Before intraperitoneal treatment with STZ (Sigma-Aldrich, St. Louis, MO), Wistar rats were allowed free access to normal food and water. On the experimental day, rats received intraperitoneal injection of STZ dissolved in 0.1 M sodium citrate buffer (pH 4.5) to a final concentration of 65 mg/kg and all rats were provided 10% sucrose water. At first week following injection of STZ, blood glucose levels of rat from acquired blood samples were tested using a glucometer.
STZ-induced diabetes
Male Wistar rats, 4 months old (National Experimental Animals Production Center, Taiwan), were caged in pairs and maintained on rodent chow and water ad libitum. Rats with diabetes were induced by a single intraperitoneal injection of STZ (50 mg/kg; Sigma-Aldrich). After one-week injection, the blood taken form the tail and blood glucose was measured. Rats with blood glucose >300 mg/dL were defined as successful induction of diabetes and then used for subsequent experiments. To equalize blood glucose level at 200 mg/dL, diabetic rats were subcutaneously administered intermittent-acting insulin (1-2 U/kg; Montards Novo Nordisk A/S, Frankfurt, Germany) once a day until the animals were killed with an overdose of sodium pentobarbital.
Animal model
The dorsum of the rats was shaved, and a 6 × 5 cm patch was drawn on the dorsal skin. The palpable hip joints were used as anatomical landmarks for defining the base of the wound defect. Incisions were made under sterile conditions, and the entire flap was undermined below the level of the dorsal fascia. The skin flap was excised to create a skin defect with an area of 6 × 5 cm. The margin of the wound defect was sutured in place with 4-0 silk sutures to prevent wound contracture. The wound was then temporarily covered with transparent Tegadermt (3M HealthCare, Borken, Germany) until ESWT was initiated. Following surgery, the rats were returned to their cages in the animal holding room after they had regained consciousness.
Experimental design
Male Wistar rats were divided into four groups (N = 8 per group). Anesthesia was administered via an intraperitoneal injection of 6% chloral hydrate (5 mL/kg; Riedel-de Haëns, Schnelldorf, Germany), along with an intramuscular injection of atropine (0.1 mg/kg) to reduce the secretion of saliva during and after the surgery. In the rats in group I (normal control group, NC), the dorsal skin defect was created but was not treated with ESWT. In the diabetic rats in group II (diabetic control group, Control), the dorsal skin defect was created but was not treated with ESWT. All rats were anesthetized during ESWT ( Figure 1A ).
In the diabetic rats in group III (ESWT), the dorsal skin defect was created and subsequently treated with defocused ESW (MTS Reflector Type CP155, MTS Europe GmbH, Konstanz, Germany) 800 impulses at 10 kV, equivalent to an energy flux density of 0.09 mJ/mm 2 in a two sessions on post-wounding days 3(−D4) and 7 (D0). The animals in group IV (ESWT + Avastin) were pretreated per day with Avastin (Roche) in 3 mg/kg body weight from postwounding (−D7) continued to day 7 (D0). One flowchart of the trials in different group is presented in Figure 1B .
The ESWT were applied to eight areas (100 impulse/area × 8 areas in all wound edges) along the margin of the dorsal wound. The time taken to administer 800 ESWT impulses was approximately 20 minutes. Ultrasound transmission gel (Pharmaceutical Innovations Inc., Newark, NJ) was applied as the contact medium between the ESWT apparatus and the skin. The term "energy flux density" represents the maximum amount of acoustic energy transmitted per pulse through an area of 1 mm 2 . The term "energy" describes the total acoustic energy carried by each shock wave. Thus, the total energy is the accumulated energy flux density as they integrated over the entire region. The dosage and timing with which ESWT was administered in this study were mimicked on the basis of our previous studies. 19 
Estimation of the wound-healing area
The wound-healing area was assessed once a week after the operation using the template technique, which has been described previously. By macroscopic observation, a distinct The flowchart of the time table was schemed in this article. The flowchart of the time table was schemed in this study. Group I (NC) included normal control rats that did not receive ESWT. Group II (C) included diabetic control without treated ESWT. Group III (ESWT) was treated with two sessions of defocused-ESWT on postoperative days 3 and 7. Group IV (ESWT + Avastin) was subjected to pretreated with one kind of vascular endothelial growth factor inhibitor (Avastin) 3 mg per rat body weight (kg) and the treated with two sessions of ESWT on postoperative days 3 and 7. The punch biopsies from the wound edges were performed at the same time periods as indication. demarcation line in the unhealed tissue area was traced onto a transparent graph paper. The area traced was cut and measured. The healed area, given by the expression (1 − A 1 /A 0 ) × 100%, was calculated from the original wound area (6 × 5 = 30 cm 2 as A 0 ) and the unhealed area (A 1 ) once a week till the entire wound had healed. 21, 22 Immunohistochemical staining Immunohistochemical (IHC) semi-quantitative staining was performed as described previously, using a horseradish peroxidase-diaminobenzidine (HRP-DAB) staining kit (R&D Inc., Minneapolis, MN). 21, 22 The biopsy was punched on days 6 and 13 post-wounding in controls without ESWT and on days 3 and 10 after the last session of ESWT (from day 10 to day 20 post-wounding) ( Figure 1B) . Polyclonal antibodies against VEGF, eNOS, and Ki-67 (Santa Cruzs, Santa Cruz, CA) were used as the primary antibodies, and the sections were incubated with these antibodies at 1:100 dilutions in phosphate-buffered saline for 1 hour. The sections were then incubated with biotinylated goat anti-rabbit antibodies for 30 minutes. The specific binding of the secondary antibodies to the primary antibodies was visualized using HRP for the enzymatic conversion of the chromogenic substrate 3,3
0 -DAB into a brown precipitate. The sections were mounted, cleared, cover-slipped, and examined using a Zeiss fluorescence microscope (Zeiss, Gottingen, Germany).
Quantitative real-time polymerase chain reaction
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the instructions by the manufacturer. Total RNA (1 μg) was reverse-transcribed using an oligo(dT) 18 primer and AMV reverse transcriptase. A realtime quantitative polymerase chain reaction (qRT-PCR) was performed using the ABI Prism 7300 Sequence Detector System (Applied Biosystems, Foster City, CA). The expression levels related to MAPK pathway were analyzed with qRT-PCR using a TaqMan ® Gene Expression Assays (Table 1) .
Data management and statistics analysis
Experimental results are presented as the means standard error (SE). One-way analysis of variance (ANOVA) was performed to determine the differences among the five groups with a normal distribution. A post hoc comparison was performed using the Tukey method. A value of p <0.05 was considered statistically significant.
RESULTS
VEGF is crucial for ESWT enhance diabetic wound healing
The overall results indicated that the wound size was significantly reduced in the ESWT-treated rats compared to that of the control (Figure 2A ). The complete wound-healing time was statistically shorter in ESWT-treated rats compared to that in diabetic controls without treatment (5.7 AE 0.6 weeks vs. 9.8 AE 0.4 weeks, p < 0.001) ( Figure 2B ). However, the wound-healing time was significantly increasing in the ESWTpretreated-Avastin group compared to that in the ESWT-treated rats group (9.2 AE 0.4 weeks vs. 5.7 AE 0.6 weeks). Moreover, the wound-healing time of the ESWT-pretreated-Avastin group was similar to that in the diabetic group. These analytical findings indicated that the VEGF may play an important role in the ESWT-enhancing diabetic wound-healing process.
VEGF is crucial for ESWT up-regulates angiogenesis
The degree of angiogenesis was assessed in terms of the VEGF and eNOS expression levels in the wound edge, which were determined by performing IHC. The expression levels of VEGF were evidently up-regulated, particularly in the fibroblasts and endothelial cells (EC), in the ESWT group on days 3 and 10 after ESWT (days 6 and 13 after wounding), as compared with the rats in the control group. However, these expression levels were significantly reduced in ESWTpretreated-Avastin group (Figure 3 ). In addition, the eNOS expression levels along the wound edge, particularly in the fibroblasts and EC, were significantly increased in the ESWT group on days 3 and 10 as compared with the rats in controls (Figure 4) . Nevertheless, the expression levels of eNOS were suppressed after Avastin, a kind of VEGF inhibitor, pretreated with ESWT in diabetic rats. This showed that ESWT substantially up-regulated the expression of VEGF and eNOS.
VEGF is involved in ESWT up-regulation of cell proliferation
Cellular proliferation was analyzed in terms of Ki-67 expression levels in the wound edge, which were determined by performing HRP-DAB IHC staining. The staining results revealed a significant increase in the Ki-67 expression level, especially in the fibroblasts in the basal epidermal and subcutaneous layers, in the ESWT group on days 3 and 10 after the last ESWT impulses when compared with rats in the control group ( Figure 5 ). However, after pretreatment of Avastin, the expression levels of Ki-67 were significantly decreased on the ESWT in the diabetic wound-healing process. Table 2 summarizes the IHC staining of the average percentage of positive-labeled cell expression in the wound margin.
ESWT accelerate diabetic wound healing by regulation of VEGF-related MAPK pathway VEGF has been shown to promote angiogenesis by activating multiple-signal pathway, such as the ERK MAPK pathway. 23, 24 Raf/MEK/ERK signaling is required for VEGF-induced endothelial proliferation. 25 Because of limited samples, we detected MAPK signaling-related genes' Figure 3 . Expression of vascular endothelial growth factor (VEGF) by using immunohistochemical (IHC) staining. Extracorporeal shockwave therapy (ESWT) up-regulated the VEGF expression levels at the junction zone of the wound edge, as determined by horseradish peroxidase-diaminobenzidine IHC staining. In this study, IHC analysis was conducted to detect genesis in the wound in terms of the VEGF expression levels; the results revealed a marked increase in its expression levels at the wound edge, especially in the fibroblasts and endothelial cells on days 3 and 10 after ESWT as compared with the control rats. The indicated signals were statistically significant (p < 0.001). NC, normal control; C, diabetes control without treatment; ESWT, two sessions of ESWT; and ESWT + Avastin, two sessions of ESWT pretreatment of Avastin. The scale bar is 5 mm. [Color figure can be viewed at wileyonlinelibrary.com] mRNA levels by quantitative RT-PCR instead traditional Western blotting at early stage (3 days) and late stage (10 days) of wound healing. We found that highly gene expression of Kras, Raf1, Mek1, Jnkk, Jnk, and Jun at early stage (3 days) in the ESWT group, as compared to that in controls ( Figure 6 ). However, pretreatment with anti-VEGF antibody (Avastin) strongly suppressed the gene expression of MAPK pathway. These results indicated VEGF activates the Ras/Raf/Mek1/Jnkk/Jnk/Jun pathway in ESWT-enhanced wound healing of STZ-induced DM model (Figure 7) .
DISCUSSION
Previous studies have reported many strategies for wound healing in diabetic patients. 17, 26, 27 Although poor diabetic wound healing is still a major complication resulting in morbidity or death, tissue ischemia induced by inadequate neovascularization are believed to be the principal factors of poor wound healing. [28] [29] [30] In this study, we assessed the effects of ESWT on wound healing and investigated the underlying mechanisms by using a dorsal skin defect in a STZ-induced diabetes rodent model. The experimental results indicated that the wound size was significantly reduced in the ESWT-treated rats compared to that of the control. The complete wound-healing time was statistically shorter in ESWT-treated rats compared to that in diabetic controls without treatment. However, the wound-healing time was significantly increasing in the ESWT-pretreated-Avastin group compared to that in the ESWT-treated rats group. Moreover, the wound-healing time of the ESWT-pretreatment-Avastin group was similar to that in the diabetic group. This showed that the VEGF may play an important role in the ESWT-enhancing diabetic wound-healing process.
Studies in mice have contributed to the identification of some angiogenic growth factors, such as VEGF and plateletderived growth factor in healing wounds. In particular, VEGF is present at elevated levels during the first phases of Figure 4 . Expression of endothelial nitric oxide synthase (eNOS) by using immunohistochemical (IHC) staining. Extracorporeal shockwave therapy (ESWT) up-regulated the eNOS expression levels at the junction zone of the wound edge, as determined by horseradish peroxidase-diaminobenzidine IHC staining. In this study, IHC analysis was conducted to detect genesis in the wound in terms of the eNOS expression levels; the results revealed a marked increase in its expression levels at the wound edge, particularly in the endothelial cells and fibroblasts on days 3 and 10 after ESWT as compared with the controls. The indicated signals were statistically significant (p < 0.001). NC, normal control; C, diabetes control without treatment; ESWT, two sessions of ESWT; and ESWT + Avastin, two sessions of ESWT pretreatment of Avastin. Scale bar is 5 mm. [Color figure can be viewed at wileyonlinelibrary.com] wound repair, but its expression declines as the healing process is completed. Angiogenic therapy may have a positive effect in the formation of granulation tissue through collagen deposition, epithelialization, and capillary growth. 10 Our previous study 21 has showed that optimal session of ESWT significantly enhance diabetic wound healing associated with Figure 5 . Expression of Ki-67 by using immunohistochemical (IHC) staining. Cellular proliferation was analyzed in terms of Ki-67 expression levels in the wound edge, which were determined by performing horseradish peroxidase-diaminobenzidine IHC staining. The staining results revealed a significant increase in the Ki-67 expression level, especially in the fibroblasts in the basal epidermal and subcutaneous layers, in the extracorporeal shockwave therapy (ESWT) groups on days 3 and 10 after the last ESWT impulses when compared with rats in the control group. However, after pretreatment of Avastin, the expression levels of Ki-67 were significantly decreasing on the ESWT in the diabetic wound-healing process (p < 0.001). NC, normal control; C, diabetes control without treatment; ESWT, two sessions of ESWT; and ESWT + Avastin, two sessions of ESWT pretreatment of Avastin. Scale bar is 5 mm. [Color figure can be viewed at wileyonlinelibrary.com] Abbreviations: eNOS: endothelial nitric oxide synthase; ESWT, extracorporeal shockwave therapy; Ki-67: proliferating cell nuclear antigen; VEGF: vascular endothelial growth factor; NC, normal control; C, diabetes control without treatment; ESWT, two sessions of ESWT; and ESWT + Avastin, two sessions of ESWT pretreatment of Avastin. *significant differences were analyzed by one-way ANOVA.
increasing neo-angiogenesis, tissue regeneration, and topical anti-inflammatory response. Cytokine expressions, including VEGF, TGFβ, FGF, nitric oxide, eNOS, and cell proliferation factors such as PCNA, are also involved in ESWT. However, cells stimulated by large dose of ESWT could suppress the expression of angiogenic factors, thereby resulting in cell apoptosis. In this study, IHC analysis was performed to assess the protein expression in the wound edge after ESWT. The experimental results indicated that VEGF expression was significantly elevated in the wound margin area, particularly in the EC and fibroblasts on days 3 and 10 after the last session of ESWT, as compared with the rats in the control group. However, these expression levels were significantly reduced in the ESWT-pretreated-Avastin group. In addition, the eNOS expression levels along the wound edge, particularly in the fibroblasts and EC, were significantly increased in the ESWT groups on days 3 and 10 as compared with the rats in controls. Nevertheless, the expression levels of eNOS were knocked down after Avastin, a kind of VEGF inhibitor, pretreated with ESWT in diabetic rats. These findings suggested that ESWT enhances wound epithelialization via increased expression of VEGF and eNOS and the induction of neovascularization in the transitional zone of the wound. Cellular proliferation and regeneration were examined in terms of the Ki-67 expression in the wound margin area. Our experimental data revealed that an optimal session of ESWT, particularly in the fibroblasts and basal epidermal layers, brought about a marked increase in the Ki-67 expression levels. However, after pretreatment of Avastin, the expression levels of Ki-67 were significantly decreasing on the ESWT in the diabetic wound-healing process. These findings indicate that topical ESWT application accelerated the wound-healing process by increasing cell proliferation, which in turn resulted in enhanced tissue regeneration.
The MAPK signaling is required for endothelial proliferation induced by VEGF which promote angiogenesis. 33, 34 Comprehensive analysis was done to compare co-expression between VEGF and Ras/Raf/MAPK signaling pathway members. In this study, MAPK pathway-related gene expressions, e.g., Kras, Raf1, Mek1, Jnkk, Jnk, and Jun, were investigated at early and late wound healing stage. The experimental results measured by Q-PCR indicated mRNA levels revealed high expression of MAPK-related pathway genes at early stage (3 days) in the ESWT group. However, pretreatment with anti-VEGF antibody (Avastin) strongly suppressed the gene expression of MAPK pathway. These results showed that VEGF activates the Ras/Raf/Mek1/Jnkk/ Jnk/Jun pathway in ESWT-enhanced wound healing of STZ-induced DM model. However, this is a very early-stage study with regard to the applications of ESWT for wound healing in a rodent model of diabetes. Many additional experiments are required to overcome the limitations of our experimental design; elucidate the mechanical effects of ESWT on cell function, the ECM, and growth factors; and examine the immunological changes occurring during the wound-healing process.
In contrast, the differences of immune responses and tissue architectures in wound healing between human and rats are limitations of this study. The rat wounding model used is not equivalent to a human's chronic nonhealing wound because the rat diabetic wound is well vascularized, whereas nonhealing wounds in persons with diabetes suffer from vascular insufficiency. 31 In clinical practice, application of ESWT to chronic diabetic foot ulcers has a positive effect. 32 Nevertheless, further study is still needed to elucidate the mechanism in details.
In summary, the present study on a rodent model indicated that treatment with multiple sessions of ESWT significantly enhanced diabetic wound healing associated with increased neovascularization and tissue regeneration. The bio-mechanism of ESWT-enhanced wound healing is through the modulation of VEGF pathway. Further investigations are required to determine the biological responses occurring after ESWT are administered to improve wound healing. However, this technique represents a feasible method for enhancing wound healing or improving compromised tissue circulation, and it may be suitable for clinical applications, such as in the treatment of chronic ischemic wound and diabetic ulcers. Conflicts of Interest: The authors have declared that no competing interest exists. None authors has financial interest in any of the products, devices, or drugs mentioned in this manuscripts
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